Filing Flows

Filing Flows › Health Care › Neuroone Medical Technologies (NMTC)

Neuroone Medical Technologies (NMTC) earnings and revenue breakdown

Latest: Q3 FY26 · 10-Q filed Aug 13, 2026 · Neuroone Medical Technologies (NMTC) Q3 FY26 earnings results →

Q3 FY26 Revenue up 16% year over year to $2.0M · 102¢ of every $1 of revenue lost · operating margin -122.9%

Neuroone Medical Technologies made $2.0M in Q3 FY26 (+16% Y/Y). Operating margin -122.9%, net loss $2.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.

Revenue$2.0M
Year over year+16%
Operating margin-122.9%
Net earnings−$2.0M
Operating cash flow−$1.1M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $2.0M in Q3 FY26, up 16% year over year and up 6% from the previous quarter.

Gross margin was 59.9%, up 6.0 points from Q3 FY25. Operating costs exceeded revenue by $2.4M, an operating margin of -122.9%. Operating expenses grew 29% against revenue growth of 16%. The fastest-growing cost line was SG&A (+35%). The quarter ended with a net loss of $2.0M, narrower than the previous quarter's $2.4M loss. Non-operating items added $418K, -21% of pre-tax earnings, so the bottom line overstates operating performance.

Operating cash flow was −$1.1M. Non-cash charges added back $47K of depreciation and amortization and $353K of share-based compensation. Working capital and other items added $525K. Capital expenditures of $20K exceeded it, leaving free cash flow of −$1.1M.

Quarterly history

Neuroone Medical Technologies revenue by quarterNeuroone Medical Technologies revenue by quarter$272KQ4 FY24$1.4MQ2 FY25$1.7MQ3 FY25$2.7MQ4 FY25$2.9MQ1 FY26$1.9MQ2 FY26$2.0MQ3 FY26
Neuroone Medical Technologies net earnings by quarterNeuroone Medical Technologies net earnings by quarter−$3.4MQ4 FY24−$2.3MQ2 FY25−$1.5MQ3 FY25−$1.6MQ4 FY25−$1.4MQ1 FY26−$2.4MQ2 FY26−$2.0MQ3 FY26
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q3 FY2610-QAug 13, 2026$2.0M+16%-122.9%−$2.0M−$1.1M
Q2 FY2610-QMay 12, 2026$1.9M+34%-128.7%−$2.4M−$1.3M
Q1 FY2610-QFeb 17, 2026$2.9M-12%-59.0%−$1.4M−$3.1M
Q4 FY2510-KDec 17, 2025$2.7M+907%-50.0%−$1.6M−$1.5M
Q3 FY2510-QAug 14, 2025$1.7M+105%-111.2%−$1.5M−$1.5M
Q2 FY2510-QMay 13, 2025$1.4M+0.7%-193.3%−$2.3M−$56K
Q4 FY2410-KDec 17, 2024$272K-63%n/m−$3.4M−$2.7M

Charts

Neuroone Medical Technologies: revenue growth, year over year and quarter over quarterNeuroone Medical Technologies: revenue growth, year over year and quarter over quarterY/YQ/Q-63%Q4 FY24+1%+400%Q2 FY25+105%+22%Q3 FY25+400%+62%Q4 FY25-12%+6%Q1 FY26+34%-36%Q2 FY26+16%+6%Q3 FY26
Latest (Q3 FY26): Y/Y +16%, Q/Q +6%.
Neuroone Medical Technologies: where the cash came from (+) and went (−), TTM to Q3 FY26Neuroone Medical Technologies: where the cash came from (+) and went (−), TTM to Q3 FY26Operating cash flow−$7.1MCash drawn (+) / kept (−)$6.0MOther financing$1.2MCapital spending−$110KTaxes on employees’ shares−$70K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Neuroone Medical Technologies: profit against cash, quarter by quarterNeuroone Medical Technologies: profit against cash, quarter by quarterNet incomeOperating cash flow−$3.4M−$2.7MQ4 FY24$1.8M$208KQ1 FY25−$2.3M−$56KQ2 FY25−$1.5M−$1.5MQ3 FY25−$1.6M−$1.5MQ4 FY25−$1.4M−$3.1MQ1 FY26−$2.4M−$1.3MQ2 FY26−$2.0M−$1.1MQ3 FY26
Latest (Q3 FY26): Net income −$2.0M, Operating cash flow −$1.1M.
Neuroone Medical Technologies: diluted shares by fiscal year (split-adjusted)Neuroone Medical Technologies: diluted shares by fiscal year (split-adjusted)11MFY2011MFY2116MFY2218MFY2327MFY2440MFY25
+270.7% since FY20: more shares outstanding (issuance, stock pay); earlier years scaled for the 2-for-1 split before FY21.
Neuroone Medical Technologies in its industry: growth against margin (111 companies, SIC 3841)Neuroone Medical Technologies in its industry: growth against margin (111 companies, SIC 3841)revenue growth, year over year →↑ operating marginmedian +10%median -9%MDLNMMMSYKBSXBDXBAXSOLVRMDDXCMWSTMMEDPODDGMEDTFXICUIMMSIIARTPENHAETNDMEMBCIRTCATECGKOSOFIXINSPNVCRUFPTATRCBVSAORTPRCTTCMDARAYANGOKIDSSKINLMATHTFLMDXGCERSSIBNTMCISTIMINFUBBNXKMTSOSURANIKDCTHRCELSGHTIRMDXTNTLUNGNPCEPDEXTELACARLLNSRSIMOBIAPYXSSIICVRXCLPTKRMDTLSIPROFSNWVCTSOIDXGUTMDRVPSNOAPREMNEPHDRIOVVOSBTCYNXGLMDAIMDNCPMINONE.SRTSSINTIVFNSPRAURXXAIRLUCDTNONINBSRNXTVTAKUSAQICUVYCOHRGNCNSYPLSEPETVFEMYOSRHCODXOBIORDGLPAVMGUTSNMTC (+16%, -100%)
Surgical & Medical Instruments & Apparatus; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Neuroone Medical Technologies

We are a medical technology company focused on (i) diagnostic, ablation and deep brain stimulation technology for brain related conditions such as epilepsy and Parkinson’s disease; (ii) ablation and stimulation for pain management throughout the body; and (iii) drug delivery including diagnostic and stimulation capabilities. We have received 510(k) clearance for four of our devices from the Food and Drug Administration (“FDA”), including: (i) our Evo cortical electrode technology for temporary (less than 30 days) recording, monitoring, and stimulation on the surface of the brain (“Evo Cortical”), (ii) our Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain (“Evo sEEG”), (iii) our OneRF ablation system for creation…

In its own words, from its 10-K, filed Dec 17, 2025.

Neuroone Medical Technologies against its Surgical & Medical Instruments & Apparatus peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +16% against the peers' median +5%. Operating margin: -122.9% against the peers' median 13.3%.

CompanyQuarterRevenueY/YOp. margin
NMTC Neuroone Medical TechnologiesQ3 FY26$2.0M+16%-122.9%
MDLN MedlineQ3 2026$7.9B+10%6.4%
MMM 3MQ3 2026$6.6B+1%23.7%
SYK StrykerQ3 2026$6.5B+8%15.9%
BSX Boston ScientificQ3 2026$5.1B+1%16.1%
BDX Becton DickinsonQ3 FY26$5.0B+5%13.3%
BAX Baxter InternationalQ3 2026$3.0B+5%7.6%
SOLV SolventumQ3 2026$1.9B-7%3.5%
RMD ResMedQ1 FY27$1.4B+6%32.0%

Source: Neuroone Medical Technologies 10-Q on SEC EDGAR · CIK 1500198 · Surgical & Medical Instruments & Apparatus

13F: who owns NMTC and who is buying

Largest holders of NMTC (13F)Largest holders of NMTC (13F)Bleichroeder LP$2.0MVanguard Capital Management LLC$1.1MBard Associates$929KGeode Capital Management, LLC$284KSio Capital Management, LLC$252KRenaissance Technologies LLC$215KPerkins Capital Management$165KVanguard Fiduciary Trust$149KBlackRock$76KNorthern Trust$65K
Funds' net buying of NMTC by quarter (13F)Funds' net buying of NMTC by quarter (13F)$162026-03$6.3M2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on NMTC

History

Every quarter: Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results · Q3 FY25 results · Q2 FY25 results · Q4 FY24 results

Compare NMTC with

中文版：Neuroone Medical Technologies（NMTC）财报

Español · Français